[1] |
WHO.WHO director-general declares the ongoing monkeypox outbreak a public health emergency of international concern[EB/OL].(2022-07-23)[2024-08-30].
|
[2] |
WHO. Fifth meeting of the international health regulations(2005)(IHR) emergency committee on the multi-country outbreak of mpox(monkeypox)[EB/OL].(2023-05-11)[2024-08-30].
|
[3] |
WHO. Mpox[EB/OL].(2024-08-26)[2024-08-30].
|
[4] |
WHO. Director-general declares mpox outbreak a public health emergency of international concern[EB/OL].(2024-08-14)[2024-08-30].
|
[5] |
WHO.2022-24 Mpox(Monkeypox)outbreak:global trends[EB/OL].(2024-08-24)[2024-08-30].
|
[6] |
BEESON A, STYCZYNSKI A, HUTSON C L,et al. Mpox respiratory transmission: the state of the evidence[J]. Lancet Microbe,2023,4(4):e277-283.
|
[7] |
|
[8] |
BERDAHL C T, KRISHNADASAN A, PATHMARAJAH K,et al. Mpox surveillance based on rash characteristics -13 emergency departments[J]. MMWR Morb Mortal Wkly Rep, 2024, 73(22):507-513. DOI: 10.15585/mmwr.mm7322a1.
|
[9] |
CAHILL S. Lessons learned from the U.S. public health response to the 2022 Mpox outbreak[J]. LGBT Health, 2023, 10(7):489-495. DOI: 10.1089/lgbt.2022.0274.
|
[10] |
国家卫生健康委员会.猴痘防控方案[EB/OL].(2023-07-23)[2024-08-30].
|
[11] |
WHO. Global strategic preparedness and response plan[EB/OL].(2023-08-11)[2024-08-30].
|
[12] |
RAINEY J J, LIN X M, MURPHY S,et al. Deployment of the national notifiable diseases surveillance system during the 2022-2023 Mpox outbreak in the United States-Opportunities and challenges with case notifications during public health emergencies[J]. PLoS One, 2024, 19(4):e0300175. DOI: 10.1371/journal.pone.0300175.
|
[13] |
WHO. Mpox-african region[EB/OL]. (2024-08-22)[2024-08-30].
|
[14] |
WORLD. Thailand confirms Asia's first known case of more contagious and deadlier version of mpox[EB/OL].(2024-08-27)[2024-08-30].
|
[15] |
BMJ Best Practice.猴痘诊断标准[EB/OL].(2022-12-22)[2024-08-30].
|
[16] |
MOSS B. Understanding the biology of monkeypox virus to prevent future outbreaks[J]. Nat Microbiol, 2024, 9(6):1408-1416.DOI: 10.1038/s41564-024-01690-1.
|
[17] |
LU J J, XING H, WANG C H,et al. Mpox(formerly monkeypox):pathogenesis,prevention,and treatment[J]. Signal Transduct Target Ther,2023,8(1):458.
|
[18] |
SUN Y H, NIE W J, TIAN D D,et al. Human monkeypox virus:epidemiologic review and research progress in diagnosis and treatment[J]. J Clin Virol, 2024, 171:105662. DOI: 10.1016/j.jcv.2024.105662.
|
[19] |
ADETIFA I, MUYEMBE J J, BAUSCH D G,et al. Mpox neglect and the smallpox niche:a problem for Africa,a problem for the world[J]. Lancet, 2023, 401(10390):1822-1824. DOI: 10.1016/S0140-6736(23)00588-3.
|
[20] |
WHO. 2022-24 Mpox(Monkeypox)outbreak:global trends-5 genomic epidemiology[EB/OL].(2024-08-24)[2024-08-30].
|
[21] |
ANDREI G, SNOECK R. Differences in pathogenicity among the mpox virus clades:impact on drug discovery and vaccine development[J]. Trends Pharmacol Sci, 2023, 44(10):719-739. DOI: 10.1016/j.tips.2023.08.003.
|
[22] |
BOISSON-WALSH A. Escalating mpox epidemic in DR congo[J]. Lancet Infect Dis,2024,24(8):e487.
|
[23] |
|
[24] |
|
[25] |
OGOINA D, DAMON I, NAKOUNE E. Clinical review of human mpox[J]. Clin Microbiol Infect, 2023, 29(12):1493-1501.DOI: 10.1016/j.cmi.2023.09.004.
|
[26] |
SATAPATHY P, MOHANTY P, MANNA S,et al. Potentially asymptomatic infection of monkeypox virus:a systematic review and meta-analysis[J]. Vaccines, 2022, 10(12):2083. DOI: 10.3390/vaccines10122083.
|
[27] |
JIANG W Y, HU Y B, YANG X,et al. Breakthrough infection and reinfection in patients with mpox[J]. Rev Med Virol, 2024, 34(2):e2522. DOI: 10.1002/rmv.2522.
|
[28] |
MOHAPATRA R K, SINGH P K, BRANDA F,et al. Transmission dynamics,complications and mitigation strategies of the current mpox outbreak:a comprehensive review with bibliometric study[J]. Rev Med Virol,2024,34(3):e2541.
|
[29] |
国家卫生健康委.猴痘防控技术指南(2022年版)[EB/OL].(2022-07-23)[2024-08-30].
|
[30] |
国家卫健委.将猴痘纳入乙类传染病管理的政策解读[EB/OL].(2023-09-15)[2024-08-30].
|
[31] |
国家卫健委.猴痘诊疗指南(2022年版)[EB/OL].(2022-06-15)[2024-08-30].
|
[32] |
全国医疗机构感染监测网,全国医院感染监控管理培训基地,国家老年疾病临床医学研究中心.猴痘医院感染防控专家共识[J].中华医学杂志,2023,103(34):2695-2703.
|